950210 — Prestige Biopharma Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeLarge CapMomentum Trap

Annual income statement for Prestige Biopharma, fiscal year end - June 30th, USD millions except per share, conversion factor applied.

	2020 June 30th	2021 June 30th	2022 June 30th	2023 June 30th	2024 June 30th
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	PROSPECTUS	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	0	0	0	0.122	0.517
Cost of Revenue
Gross Profit	—	—	-18.4	-18.6	2.33
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	9.09	16.2	109	64.2	47.2
Operating Profit	-9.09	-16.2	-109	-64.1	-46.7
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-12.5	-6.48	-175	-1.58	-41
Provision for Income Taxes
Net Income After Taxes	-12.5	-6.51	-176	-2.16	-41.3
Minority Interest
Net Income Before Extraordinary Items
Net Income	-12.5	-6.51	-176	13.3	-24.7
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-12.5	-6.51	-176	13.3	-24.7
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-1.04	-0.63	-11.4	1.72	-2.08